what’s next?

Before updating clinical guidelines or formulary decisions, project the impact across patient populations. See who is helped, who is harmed, where the trade-offs land. Identify the unintended consequences that aggregate data hides.

Test capacity allocation across facilities, specialties, and time. See where bottlenecks form under realistic demand. Identify the investments that improve patient outcomes versus those that look good in occupancy metrics.

Simulate trial designs against eligible patient populations before launching. See where recruitment will struggle, where statistical power will fall short, where ethical concerns will surface. Adjust before commitments are made.

For pharmaceuticals and medical devices, test pricing strategies against payer mix, patient access, and long-term volume. Identify pricing that sustains research investment without abandoning patients who need the product.

Model intervention strategies against realistic epidemiological scenarios. Compare lockdown, vaccination, and treatment policies against their downstream effects on health, economy, and social trust. Decide with evidence, not panic.

When facing genuine scarcity. ICU beds, transplant organs, scarce medications. Test allocation frameworks against the populations they will be applied to. See the demographic and clinical patterns each framework produces. Make decisions that can be defended ethically as well as operationally.